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Background: Fatty acid synthase (FASN) is overexpressed and hyperactivated in several human carcinomas,
including lung cancer. We characterize and compare the anti-cancer effects of the FASN inhibitors C75 and
(−)-epigallocatechin-3-gallate (EGCG) in a lung cancer model.
Methods: We evaluated in vitro the effects of C75 and EGCG on fatty acid metabolism (FASN and CPT enzymes),
cellular proliferation, apoptosis and cell signaling (EGFR, ERK1/2, AKT and mTOR) in human A549 lung carcinoma
cells. In vivo, we evaluated their anti-tumour activity and their effect on body weight in a mice model of human
adenocarcinoma xenograft.
Results: C75 and EGCG had comparable effects in blocking FASN activity (96,9% and 89,3% of inhibition,
respectively). In contrast, EGCG had either no significant effect in CPT activity, the rate-limiting enzyme of fatty acid
β-oxidation, while C75 stimulated CPT up to 130%. Treating lung cancer cells with EGCG or C75 induced apoptosis
and affected EGFR-signaling. While EGCG abolished p-EGFR, p-AKT, p-ERK1/2 and p-mTOR, C75 was less active in
decreasing the levels of EGFR and p-AKT. In vivo, EGCG and C75 blocked the growth of lung cancer xenografts but
C75 treatment, not EGCG, caused a marked animal weight loss.
Conclusions: In lung cancer, inhibition of FASN using EGCG can be achieved without parallel stimulation of fatty
acid oxidation and this effect is related mainly to EGFR signaling pathway. EGCG reduce the growth of
adenocarcinoma human lung cancer xenografts without inducing body weight loss. Taken together, EGCG may be
a candidate for future pre-clinical development.
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EGFRBackground
Fatty acid synthase (E.C.2.3.1.85; FASN) is a homodimeric
multienzymatic protein that catalyzes de novo synthesis of
long-chain fatty acids from acetyl-CoA, malonyl-CoA, and
NADPH precursors [1]. In most human tissues the diet
supplies the fatty acids needs and FASN expression is low
or undetectable. In contrast, in many human solid carcin-
omas, lipogenic enzymes (mainly FASN) are highly
expressed [2-7] and de novo fatty acids biosynthesis sup-
plies the needs of long chain fatty acids (LCFA) for energy* Correspondence: teresa.puig@udg.edu
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reproduction in any medium, provided the orproduction, protein acylation, synthesis of biological mem-
branes, DNA synthesis and cell cycle progression among
other biological processes, providing an advantage for
tumour growth and progression [3-5].
FASN inhibition that blocks lipogenic pathway and
impedes fatty acid synthesis, entails apoptosis in tumour
cells that overexpress FASN, without affecting non-
malignant cells (reviewed in ref. [8]). In this context,
FASN enzyme has became a promising target for anti-
cancer therapy, a putative biomarker of malignancy and
an indicative of prognosis for many cancers, including
lung carcinomas [5-7,9].
The oncogenic properties of FASN seem to be the result
of an increased activation of HER2 and its downstreamd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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B/mammalian target of rapamycin (PI3K/AKT/mTOR),
mitogen-activated protein kinase/extracellular signal-
regulated kinase (MAPK/ERK1/2) pathways [10-18].
The use of FASN inhibition as anticancer therapy was
first described with Cerulenin (a natural antibiotic from
Cephalosporium ceruleans) that causes apoptotic cancer
cell death in vitro [19]. More recently, C75, a synthetic
analogue of cerulenin or (−)-epigallocatechin-3-gallate
(EGCG), the main polyphenolic catechin of the green tea,
have been identified as FASN inhibitors, able to induce
apoptosis in several tumour cell lines and also to reduce
the size of mammary tumours in animal models [8,20-24].
Although its selective cytotoxicity, C75 has been discarded
in many cancer models due to its side effects: anorexia and
body weight loss. In contrast, we have demonstrated that
in SKBr3 breast cancer cells EGCG has similar effects as
C75 in inhibiting FASN and it does not induce CPT activ-
ity in vitro, neither weight loss in vivo [11,25,26], opening
new perspectives in the use of green tea polyphenols or its
derivatives as anti-cancer drugs alone or in combination
with other therapies.
Here we compare the effects of C75 and EGCG on
lipogenesis (FASN activity), fatty acid oxidation (CPT ac-
tivity), cellular proliferation, induction of apoptosis and
cell signaling (EGFR, ERK1/2, AKT and mTOR) in A549
lung carcinoma cells. We also evaluated their anti-cancer
activity and their effect on body weight with a mice
model of A549 lung cancer xenograft. We examined
EGCG as a potential drug for clinical development in
adenocarcinoma of lung cancer that accounts for 40% of
non-small-cell lung cancers (NSCLC), the most common
type of lung cancer [27].
Methods
Cell Lines and Cell Culture
A549 lung cancer cells were obtained from the American
Type Culture Collection (ATCC, Rockville, MD, USA),
and were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM, Gibco, Berlin, Germany) containing
10% heat-inactivated fetal bovine serum (FBS, HyClone
Laboratories, Utah, USA), 1%L-glutamine, 1% sodium
pyruvate, 50 U/mL penicillin, and 50 μg/mL strepto-
mycin (Gibco). Cells were routinely incubated at 37 °C in
a humidified atmosphere of 95% air and 5% CO2.
Growth Inhibition Assay
EGCG, C75 and 3–4,5-dimethylthiazol-2-yl-2,5-diphe-
nyltetrazolium bromide (MTT) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Dose–response
studies were done using a standard colorimetric MTT
reduction assay. Briefly, cells were plated out at a density
of 3 × 103 cells/100 μL/well in 96-well microtiter plates.
Following overnight cell adherence fresh medium alongwith the corresponding concentrations of EGCG and
C75 were added to the culture. Following treatment,
media was replaced by drug-free medium (100 μL/well)
and MTT solution (10 μL of a 5 mg/mL), and incubation
was prolonged for 2,5 h at 37°C. After carefully removing
the supernatants, the MTT-formazan crystals formed by
metabolically viable cells were dissolved in DMSO (100
μL/well) and absorbance was determined at 570 nm in a
multi-well plate reader (Spectra max 340PC (380), Bio-
Nova Cientifica s.l., Madrid, Spain). Using control optical
density OD values (ODCTRL) and test OD values (ODT-
EST), the agent concentration that caused 50% growth in-
hibition (IC50 value) was calculated from extrapolating in
the trend line obtained by the formula (ODCTRL - ODT-
EST)*100/ODCTRL.
Fatty Acid Synthase Activity Assay
Cells were plated out at a density of 1x105 cells/500 μL/
well in 24-well microtiter plates. Following overnight cell
adherence media was replaced by DMEM supplemented
with 1% lipoprotein deficient Fetal Bovine Serum (Sigma)
along with the corresponding IC50 concentrations of C75
(72 μM) and EGCG (265 μM) or DMSO. For the last 6 h
of the treatment, ([1,2-14C] Acetic Acid Sodium salt
(53,9 mCi/mmol) (Perkin Elmer Biosciences, Waltham,
MA, USA) was added to the media (1 μCi/mL). Cells were
harvested and washed twice with phosphate-buffered sa-
line (PBS) (500 μL) and once with Methanol:PBS (2:3)
(500 μL). The pellet was resuspended in 0,2 M NaCl (100
μL) and broke with freeze-thaw cycles. Lipids from cell
debris were extracted by centrifugation (2000 g, 5 min)
with Chloroform:Phenol (2:1) (350 μL) and KOH 0,1 M
(25 μL). The organic phase recovered is then washed with
Chloroform:Methanol:Water (3:48:47) (100 μL) and evapo-
rated in a Speed-vac plus SC110A (Savant). The dry-
pellets were resuspended in ethanol and transferred to a
vial for radioactive counting.
Mitochondria Isolation of A549 Cells
Cells were grown to confluence in 10 mm dishes and col-
lected in PBS (100 μL/dish). The pellet was resuspended in
Buffer A (150 mM KCl, 5 mM Tris–HCl, pH 7.2) (125 μL/
dish), and disrupted using a glass homogenizer (10 cycles
with tight fitting pestle and 10 cycles with light one). Mito-
chondria were collected by centrifugation (16000 g, 5 min
at 4°C), resuspended in Buffer A and quantified using
Bradford-based Bio-Rad assay (BioRad Laboratories,
Hercules, CA, USA). At this step mitochondria could be
used for total CPT activity measurement.
Carnitine Palmitoyltransferase (CPT) Activity Assay
CPT activity was assayed by the forward exchange method
using L- [methyl-3H] Carnitine hydrochloride (82 Ci/
mmol) (Perkin Elmer Biosciences) as we previously
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standard enzyme assay mixture (1 mM L-[3H]carnitine
(~5000 dpm/nmol), 80 μM palmitoyl-CoA (Sigma),
20 mM HEPES (pH 7.0), 1% fatty acid-free albumin
(Roche Sciences, Mannheim, Germany), 40–75 mM KCl
and the corresponding IC50 concentrations of C75
(72 μM) and EGCG (265 μM) or DMSO when indicated.
Reactions were initiated by addition of A549 isolated mito-
chondria (100 μg) and all incubations were done at 30°C
for 3 min. Reactions were stopped by addition of 6% Per-
chloric Acid and then the product [3H]-palmitoylcarnitine
was extracted with butanol at low pH and was transferred
to a vial for radioactive counting.
Western Blot Analysis of Tumour and Cell Lysates
The primary mouse monoclonal antibody for FASN was
from Assay designs (Ann Arbor, MI, USA). Monoclonal
anti–β-actin mouse antibody (clone AC-15) was from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Rabbit polyclonal antibodies against poly-(ADP-ribose)-
polymerase (PARP), AKT, phospho-AKTSer473, ERK 1/2,
EGFR, phospho-EGFRTyr1068, mTOR, phospho-mTOR-
Ser2448 and mouse monoclonal antibody against phospho-
ERK1/2Thr202/Tyr204, were from Cell Signaling Technology,
Inc (Danvers, MA, USA). A549 cells were harvested fol-
lowing treatment of A549 cells with EGCG or C75.
Tumour tissues were collected from A549 human lung
cancer xenografts at the end of the in vivo experiment.
Cells and tumour tissues were lysed with ice-cold in lysis
buffer (Cell Signaling Technology, Inc.) containing 1 mM
EDTA, 150 mM NaCl, 100 μg/mL PMSF, 50 mM Tris–
HCl (pH 7.5), protease and phosphatase inhibitor cocktails
(Sigma). Protein content was determined by the Lowry-
based Bio-Rad assay (BioRad Laboratories). Equal amounts
of protein were heated in LDS Sample Buffer and Sample
Reducing Agent from Invitrogen (California, USA) for
10 min at 70°C, separated on 3% to 8% or 4% to 12% SDS-
polyacrylamide gel (SDS-PAGE) and transferred to nitro-
cellulose membranes. After blocking, membranes were
incubated overnight at 4°C with the corresponding primary
antibody. Blots were washed in PBS-Tween, incubated for 1
hour with corresponding peroxidase-conjugated secondary
antibody and revealed using a commercial kit (Super Signal
West Pico or Super Signal West Femto chemiluminescent
substrate from Thermo scientific (Illinois, USA) or Immobi-
lon Western HRP Substrate from Millipore (Massachusetts,
USA)). Blots were re-proved with an antibody against β-
actin as control of protein loading and transfer.
In vivo Studies: Human Lung Tumour Xenograft and Long-
term Weight Loss Experiments
Experiments were conducted in accordance with guide-
lines on animal care and use established by Biomedical Re-
search Institute of Bellvitge (IDIBELL) InstitutionalAnimal Care and Scientific Committee (AAALAC unit
1155). Tumour xenograft were established by subcutane-
ous injection of 10 x 106 A549 cells mixed in Matrigel (BD
Bioscience, California, USA) into 4–5 week old athymic
nude BALB/c female’s flank (Harlan Laboratories, Gannat,
France). Female mice A549 (12 wk, 23–25 g) were fed ad
libitum with a standard rodent chow and housed in a
light/dark 12 h/12 h cycle at 22°C in a pathogen-free facil-
ity. Animals were randomized into three groups of five
animals in the control and four animals in the C75 and
EGCG-treated groups. When tumours’ volume were palp-
able (reached around 35–40 mm3) each experimental
group received an i.p. injection once a week of C75 or
EGCG inhibitor (40 mg/kg) or vehicle alone (DMSO), dis-
solved in RPMI 1640 medium. Tumour volumes and body
weight were registered the days of treatment and four days
after every treatment until 33 days after first administra-
tion. Tumours were measured with electronic calipers,
and tumour volumes were calculated by the formula:
π/6× (v1× v2× v2), where v1 represents the largest tumour
diameter, and v2 the smallest one. At the end of the ex-
periment, all mice were euthanized and tumour tissues
were collected.
Statistical Analysis
In vitro results were analysed by Student’s t-test or by
one-way ANOVA using a Bonferroni test as a post-test.
All data are mean± standard error (SE). All observations
were confirmed by at least three independent experi-
ments. In vivo drug efficacy experiment results were ana-
lyzed using the non-parametric Wilcoxon test comparing
repeated measurements (tumour volume). Data are the
median of tumour volume of 4 or 5 animals. Statistical
significant levels were p < 0.05 (denoted as *) and
p < 0,001 (denoted as **).
Results
Effect of EGCG and C75 on FASN and CPT Activities in
A549 Cells
In order to evaluate the specificity of EGCG and C75 for
FASN, we analyzed their effect on FASN and CPT system
activities. A549 cells were treated for 24 hours with IC50
concentration values of C75 (72 ± 2,8 μM) or EGCG
(265 ± 7,1 μM) [Additional file 1: Figure S1]. As shown in
Figure 1, C75 and EGCG significantly reduced FASN ac-
tivity in A549 cells compared to control cells (remaining
FASN activity of 3,1 ± 0,6% and 10,7 ± 1,5%, p = 0,000;
both). Significant changes in FASN protein levels were
also observed in EGCG-treated cells but not in control
or C75-treated cells, as assessed by Western blotting
(Figure 2). The effect of both compounds on CPT en-
zymatic activity was assayed in A549 isolated mitochon-
dria, as described in the Material and Methods section.
EGCG had no effect on CPT activity (115 ± 12%, respect
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a significant activation of CPT system (131 ± 11%, respect
to control; p = 0,294).
Analysis of the Effect of EGCG and C75 on Apoptosis and
Cell Signaling in A549 Cells
Apoptosis and induction of caspase activity were
checked with cleavage of PARP in Western blotting ana-
lysis. Apoptosis was not detected in A549 non-treated
cells. In A549 cells treated for 6, 12 and 24 hours with
IC50 concentration values of C75 or EGCG (Additional
file 1: Figure S1), there was an increase in the levels of
89 kDa PARP product in a time-dependent manner
(Figure 3). We examined the effects of EGCG and C75 on
the phosphorylated and the total levels of EGFR (p-EGFR),
HER2 (p-HER2), HER3 (p-HER3), HER4 (p-HER4) and
its related downstream AKT, ERK1/2 and mTOR pro-
teins. Results in Figure 3 confirmed that A549 cells trea-
ted with EGCG showed a marked decrease in the
phosphorylated forms of EGFR, AKT, ERK1/2 and mTOR
within 6 hours of EGCG treatment, with no changes in
the total levels of the corresponding proteins. In contrast,
C75 treatment needs up to 48 hours just to detect a par-
tial decrease on total levels of EGFR protein and on p-
AKT protein. Phosphorylated and total protein levels of
HER2 (p-HER2), HER3 (p-HER3) and HER4 (p-HER4)
did not change after C75- or EGCG-treatment (Data
not shown).
In Vivo Analysis of EGCG and C75 on Human Lung Cancer
Xenografts
To explore the potential effectiveness of EGCG and C75
for lung cancer treatment in vivo, we treated athymic
nude mice with A549 human lung cancer xenograft. In0
20
40
60
80
100
120
140
FASN
%
 
En
zy
m
e
 
Ac
tiv
ity
**
**
Figure 1 EGCG inhibits FASN activity in A549 cancer cells with no cha
with C75 (72 μM) and EGCG (265 μM) and FASN activity was assayed by co
mitochondria from A549 cells were assayed for CPT activity in the presence
Material and Methods. Bars represent the remaining enzyme activity in A54
separate experiments. ** p < 0,001 versus control, by one-way ANOVA or Stcontrol animals, on final day the median of the tumour
volume (519 mm3 on day 33) was significantly different
from the starting median tumour volume (33 mm3 on
day 0, p = 0,04) and this trend (was similar from days 12
to 33 in control animals’ group (Data not shown). In the
experimental animals, the median of the tumour volume
of C75- and EGCG-treated animals on day 33 (290 and
224 mm3, respectively) wasn’t significantly different from
the median of the tumour volume on the starting day
(40 and 36 mm3, respectively; p = 0,07 both), those point-
ing out that the treatment with the anti-FASN com-
pounds C75 and EGCG prevents the growth of A549
xenografts (Figure 4A). C75 and EGCG-treated tumours
showed apoptosis by induction of PARP cleavage without
any change in the total levels of FASN protein
(Figure 4A). In EGCG-treated animals we do not find
significant changes on fluid, food intake, body weight or
other toxicity parameters (data not shown) versus con-
trol animals, after 33 days of weekly treatment with
40 mg/Kg of EGCG (Figure 4B). C75-treated animals
showed a marked decrease of body weight (close to 6%)
after each i.p. administration, which was especially re-
markable in the first 20 days of treatment (Figure 4B).
Discussion
Levels of FASN expression in different human carcin-
omas attracted considerable interest of this enzyme as a
target for therapy [10,11]. In this study, we show that
adenocarcinoma of lung cancer, is among the foremost
of cancers that could potentially be treated by inhibiting
FASN.
C75 has been studied in A549 lung cancer xenografts
[28] where it induces a transient and reversible growth
inhibition. EGCG anti-cancer effects in lung cancer haveCPT
*
nge on CPT system activity. A549 Cells were treated for 24 hours
unting radiolabelled fatty acids synthesized de novo. Isolated
of DMSO (control), C75 (72 μM) or EGCG (265 μM), as described in
9 treated cells or mitochondria. Data are means ± SE from at least 3
udent’s t-test.
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Figure 4 EGCG inhibits A549 xenograft growth and do not
induce in vivo weight loss. A, once a week i.p. administration of
40 mg/kg of C75 (●) or EGCG (●) during 33 days blocked the
growth of A549 lung cancer xenografts compared to control animals
(●). Circles represent individual increase in tumour volume at final
day (day 33) and horizontal lines represent the median value for
each experimental group. C75 and EGCG-treated tumours showed
apoptosis, whereas FASN protein levels did not change. Treated and
control tumours were lysed and equal amounts of lysates were
subjected to Western blot analyses with anti-PARP and anti-FASN.
Blots were reprobed for β-actin as loading control. Gels shown are
representative of those obtained from two independent
experiments. B, EGCG treatment does not induce weight loss. The
body weight of each mouse was measured before and weekly after
treatment with C75 or EGCG (40 mg/Kg/day for 33 days) or vehicle
control. Data are expressed as percentage of initial body weight and
represent mean values ± SE for each experimental group.
Figure 2 EGCG blocks phosphorilation of EFGR, HER2, ERK1/2,
AKT and mTOR in A549 cells. A549 cells were treated for 6, 12, 24
and 48 hours with C75 (72 μM) and 6, 12 and 24 hours with EGCG
(265 μM), and equal amounts of lysates were immunoblotted with
anti-EGFR, anti-HER2, anti-ERK1/2, anti-AKT, anti-mTOR and anti-FASN
antibodies. Activation of the protein under study was analyzed by
assessing the phosphorylation status using the corresponding
phospho-specific antibody. Total amounts of HER2 and AKT proteins
remain unchanged. Blots were reproved with an antibody for β-actin
to control for protein loading and transfer. Gels shown are
representative of those obtained from three independent
experiments.
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eral mechanisms of action have been proposed, such as
G3BP1 (GTPase activating protein (SH3 domain) bind-
ing protein) inhibition [29], generation of Reactive Oxy-
gen Species (ROS) [30] or induction of p53-dependent
transcription [31].
To further investigate the implications of FASN inhib-
ition in lung adenocarcinoma, we have analyzed the
blockage of FASN by EGCG and C75 in A549 lung can-
cer cells. Firstly, we ensured similar levels of FASN in-
hibition by C75- and EGCG-treatment (96,9% and 89,3%Figure 3 EGCG and C75 induce apoptosis in A549 cells.
Induction of caspase activity was confirmed by PARP cleavage. A549
cells were treated with C75 (72 μM) or EGCG (265 μM) for 6, 12 and
24 hours, and equal amounts of lysates were immunoblotted with
anti-PARP antibody, which identified the 89 kDa (cleavage product)
band. Blots were reproved for β-actin as loading control. Gels shown
are representative of those obtained from three independent
experiments.of control, respectively). As C75 had no effect on the
abundance of FASN protein levels and EGCG dimin-
ished the levels of this enzyme, it is probable that in the
EGCG-treated cells, the reduction of FASN activity could
be in part consequence of the reduced FASN protein
levels.
The inhibition of FASN activity by EGCG and C75 was
accompanied by an induction of apoptosis, and changes
in cell growth and proliferation signaling pathways. The
active phosphorylated form of EGFR (p-EGFR) was
completely abolished after 6 hours of exposure to
EGCG. Consequently, phosphorylated forms of ERK1/2
(p-ERK1/2), AKT (p-AKT) and mTOR (p-mTOR) were
also markedly decreased. It is remarkable that
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longed exposure (48 hours), only partially decreased
total levels of EGFR and phosphorylated levels of AKT
(p-AKT). Several data supported a relationship between
HER2 and FASN in breast cancer, head and neck car-
cinomas, HER2-overexpressed fibroblasts and other
carcinomas [11,32-35]. Furthermore, some authors have
demonstrated the blocking effects of the FASN inhibi-
tor EGCG on all members of epidermal growth factor
receptor (ErbB) family [11,36-38].
This is the first evidence that EGFR is involved in the
regulation of FASN expression in a lung cancer model
with EGFR-overexpression. EGFR may be another
EGCG-direct target that through inhibition of its down-
stream signalers (Akt, ERK1/2 and mTOR) is able to
down-regulate FASN expression at two different levels:
1, at the transcriptional level through the sterol response
element-binding proteins 1c (SREBP-1c), the FASN-
transcription factor mediated by PI3K/Akt and MAPK/
ERK1/2 pathways [39]; 2, at the translational level,
through Akt-mTOR-signaling and its downstream effec-
tors, eIF4G and S6K (reviewed in ref [40]) as seen in
breast cancer [41] and in human hepatoma cells [42].
In addition, we corroborate a FASN-ErbB loop,
described in breast cancer. The FASN disruption
impedes synthesis of lipids, which are integrated in
membrane lipid raft in which cell surface receptors, ErbB
among others, accommodate and sense to tumourigenic
pathways [43]. C75 is a direct and competitive inhibitor
of FASN [21]. Consequently, we have seen a strong and
fast inhibition of FASN activity with C75 treatment and
a later effect on levels of EGFR and phosphorylation of it
downstream effector Akt (p-Akt), what brings us to cor-
roborate the idea of a FASN-lipid rafts-ErbB inhibition
loop.
An important result of our study is the in vivo drug-
efficacy study and long-term body weight evaluation.
EGCG and C75 markedly blocked the growth of A549
lung cancer xenografts while the tumour volumes of con-
trol animals growth significantly until the final day study.
C75-treated mice showed a marked decrease in body
weight after each administration (close to 6% of initial
body weight). This result accords to the data that C75 is
able to stimulate CPT system and fatty acid β-oxidation,
which has been related to the severe decrease of food in-
take and induction of weight loss in rodents [44]. In con-
trast, we have not observed a significant decrease in body
weight in the animals treated for 33 days with EGCG.
A key feature of EGCG is that does not affect CPT ac-
tivity (as it is shown in vitro in Figure 1) and, conse-
quently, it does not induce weight loss in experimental
animals. This result in a lung cancer model are in agree-
ment with our previous findings in a mouse breast can-
cer model [11] and reinforces the hypothesis that CPT-activation is the cause of weight loss in xenografts mod-
els. Our data also reveal for the first time that the effects
of EGCG in lung carcinoma involve different pathways
than C75 but also that the undesirable side effects
observed in C75 treated-mice are not produced in
EGCG-treated mice.
Conclusions
In conclusion, the work reported here supports the devel-
opment of EGCG as a FASN inhibitor for adenocarcinoma
lung cancer treatment. EGCG acts as potent and
lipogenic-selective inhibitor of FASN, and do no exhibit
adverse effects on body weight, therefore holding promise
for further target-directed anti-cancer drug studies either
alone or co-administered with other antitumoural drugs.
Additional file
Additional file 1: Figure S1. EGCG and C75 show cytotoxic activity
in A549 human lung carcinoma cells. A549 cells were treated with
different concentrations of C75 (20 – 200 μM) or EGCG (40 – 300 μM) for
48 hours. Pale gray (●) and dark grey (●) circles represent the
percentage of A549 cell proliferation inhibition after C75 and EGCG
treatment respectively, which was determined using an MTT assay.
Results are expressed as mean percentage of inhibition in cell
proliferation from three independent experiments performed in
triplicate ± SE. PDF File Format.
Abbreviation
FASN: inhibition in lung cancer.
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